Instruments

Name Stock exchange Average volume Price Type
A. K. CA 9.3/APR27

Bombay S.E.

- - % Bond A. K. CA 9.3/APR27 Bond
A. K. CA 8.0/MAY24

Bombay S.E.

0 1,07,211 % Bond A. K. CA 8.0/MAY24 Bond
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Boerse Frankfurt Warrants

- 106 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Boerse Frankfurt Warrants

- 86.05 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Boerse Frankfurt Warrants

- 219.9 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Boerse Frankfurt Warrants

- 19.41 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Boerse Frankfurt Warrants

- 28.73 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Deutsche Boerse AG

- 193.1 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Deutsche Boerse AG

- 86.05 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat
FAKTOR OPTIONSSCHEIN - SMITH CO., A. O.

Deutsche Boerse AG

- 14.8 EUR Certificat FAKTOR OPTIONSSCHEIN - SMITH CO., A. O. Certificat

News (63)

Cosmo Announces Leadership Changes NE
Cosmo Pharmaceuticals N : ESG Report 2023 PU
Cosmo Pharmaceuticals N : Convening notice PU
Cosmo Pharmaceuticals N : Explanatory notes PU
Cosmo Pharmaceuticals N : Written proxy PU
Cosmo Pharmaceuticals N : Dieter A. Enkelmann CV PU
Cosmo Pharmaceuticals? Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA EQ
Transcript : Julius Bär Gruppe AG - Special Call
Transcript : Julius Bär Gruppe AG, 4 Months 2022 Interim Management Statement Call, May 19, 2022
Transcript : Julius Bär Gruppe AG, 2021 Earnings Call, Feb 02, 2022
EUROPEAN MIDDAY BRIEFING - Shares Little Changed, -2- DJ
Evie Kostakis to succeed Dieter Enkelmann as CFO of Julius Baer EQ
Julius Bär Gruppe : Evie Kostakis to succeed Dieter Enkelmann as CFO of Julius Baer PU
Julius Bär Gruppe AG Announces Executive Changes CI
Transcript : Julius Bär Gruppe AG, H1 2021 Earnings Call, Jul 21, 2021
Julius Bär Gruppe : Baer to develop real estate offering as part of Swiss market strategy PU
Transcript : Julius Bär Gruppe AG, 2020 Earnings Call, Feb 01, 2021
Julius Bär Gruppe : Baer slips on fears trading boom might fade RE
Transcript : Julius Bär Gruppe AG, H1 2020 Earnings Call, Jul 20, 2020
Julius Bär Gruppe : Baer slips on fears trading boom might fade RE
Transcript : Julius Bär Gruppe AG, 2019 Earnings Call, Feb 03, 2020
Julius Baer: Interim Management Statement for the first ten months of 2019 TE
Julius Baer announces new executive leadership team TE
Julius Baer Group Ltd. and Bank Julius Baer & Co. Ltd Announce New Executive Leadership Team CI
Transcript : Julius Baer Group Ltd., H1 2019 Earnings Call, Jul 22, 2019
Philipp Rickenbacher appointed CEO of Julius Baer TE
Julius Baer Group Ltd. places Swiss franc-denominated additional Tier 1 Bond TE
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting TE
Transcript : Julius Baer Group Ltd., 2018 Earnings Call, Feb 04, 2019
Transcript : Julius Baer Group Ltd., H1 2018 Earnings Call, Jul 23, 2018
Julius Bär Gruppe : Baer sees net money slowdown in 2018, on lookout for acquisitions RE
Transcript : Julius Baer Group Ltd., 2017 Earnings Call, Jan 31, 2018
Julius Baer Group Ltd. places USD-denominated Additional Tier 1 bond TE
Julius Bär Gruppe : Baer's best inflows since financial crisis lift shares RE
Transcript : Julius Baer Group Ltd., H1 2017 Earnings Call, Jul 24, 2017
Transcript : Julius Baer Group Ltd., 2016 Earnings Call, Feb 01, 2017
Julius Baer Group Ltd. successfully places a second SGD-denominated perpetual tier 1 subordinated bond TE
Transcript : Julius Baer Group Ltd., H1 2016 Earnings Call, Jul 25, 2016
Cosmo shareholders approve change of registered seat TE
Transcript : Julius Baer Group Ltd., 2015 Earnings Call, Feb 01, 2016
Julius Baer Group Ltd. successfully places SGD-denominated perpetual tier 1 subordinated bonds TE
Transcript : Julius Baer Group Ltd., H1 2015 Earnings Call, Jul 20, 2015
GAM : Results of the Annual General Meeting of GAM Holding AG GL
GAM : Change in the Board of Directors of GAM Holding AG as of the 2015 Annual General Meeting GL
Dieter Enkelmann Announces Not to Stand for Re-Election to the Board of Directors of the GAM Holding AG CI
12NextSee all

Companies (1)

ISOENERGY LTD. 574 M $
Logo IsoEnergy Ltd.

IsoEnergy Ltd. is a Canada-based diversified uranium company. The Company is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada, the United States of America, Australia, and Argentina. The Company is focused on advanci ...


Insiders

Picture Dieter A. Enkelmann
Dieter A. Enkelmann

Mr. Dieter A. Enkelmann is a Chief Financial Officer at Bank Julius Bär & Co. AG, at Julius Bär Gruppe AG, an Independent Non-Executive Director at Cosmo Pharmaceuticals NV, and a Chairman-Foundation Board at Stiftung Für Angewandte Krebsforschung. He is on the Board of Directors at Cosmo Pharmaceuticals NV. From 2003 until 2006 he was the Chief Financial Officer of Barry Callebaut AG, the world's leading manufacturer of high-quality cocoa, chocolate and confectionery products which is listed on the SWX. From 1997 to 2003 he was at Swiss Re as Head of Finance of the Business Unit Financial Services and as Head of Corporate Finance and Investor Relations, Treasury. From 1985 to 1997 he was at Credit Suisse First Boston. Mr. Enkelmann holds a law diploma from the University of Zürich.









No results for this search

  1. Stock Market
  2. Advanced search
  3. Dieter A. Enkelmann
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW